What is CAPA in Pharma?

Written By: Derek Koziol
  • 8/17/2020
  • Read Time : 2 min
capa-in-pharma-900x450

From researching, to development, to distribution, creating an effective drug within the pharmaceutical industry takes an incredible amount of time and money. Given the inherent complexity of a drug’s formula, along with increased competition and mounting pressure to drastically decrease time-to-market and costs, it’s imperative that if production issues arise, they’re addressed swiftly and effectively to avoid disaster.

With the added pressure to meet FDA standards to secure patents, ensuring a drug is safe for public consumption requires little variation in the efficacy of the drug, and without consistent effectiveness, drug manufacturers can face complaints, investigations, and even costly lawsuits.

To head off these complications before commercialization, corrective and preventative action (CAPA) plans are instrumental in reducing non-conformances and reaching the high FDA benchmarks drugs are subject to before and after going to market.

Importance of Corrective and Preventive Action in the Pharmaceutical Industry

The industry views the CAPA process as critical to their success by providing the risk-assessment necessary for pharmaceutical manufacturers to mitigate any non-conformances when they arise.

When a non-conformance does arise, whether during production or in the field, having a sound CAPA process in place to review documentation, roles and responsibilities of stakeholders, and technology involved in production helps drug manufacturers find, fix, and validate the problem without the risk of losing billions of dollars.

CAPA Procedure in the Pharmaceutical Industry

By identifying and evaluating the validity of an issue, intaking all relevant information, such as documentation or filed complaints, and appraising the potential impact, manufacturers can not only fix the non-conformance but use the information to develop processes to ensure the non-conformance does not occur again.

To address non-conformances, CAPAs put measures in place to:

  • Identify the non-conformance with a detailed, evidence-based description
  • Evaluate the situation that led to the non-conformance and the level of action needed to address the situation based on risk
  • Investigate the root cause of the problem
  • Analyze the results from the investigation
  • Create an action plan to correct the non-conformance
  • Implement the plan
  • Evaluate the implementation and effectiveness of the plan

With such prescriptive processes and documentation, if a complaint is filed or the FDA investigates or conducts an audit, the manufacturer can prove that corrective and preventative actions have been taken to mitigate non-conformances.

PLM software provides the capabilities necessary to successfully identify and plan CAPAs. With PTC’s industry-leading PLM software, Windchill, enterprises can unify engineering, quality, and regulatory teams to ensure they are coordinated and involved in correcting and preventing product errors. With Windchill, you can meet CAPA standards and demonstrate compliance with extensive failure reporting best practices. You can learn more about CAPA and Windchill here.

Tags:
  • PLM
  • Quality
  • Windchill
  • Life Sciences

About the Author

Derek Koziol

Derek Koziol has over 20 years as an experienced Continuous Improvement leader with deep expertise in Six Sigma, lean, change management and program management.

With an MBA and LSSMBB, he has led global enterprise Product Lifecycle Management (PLM) initiatives in several industries ranging from technology and automotive, to complex pharma and medical devices.